The Chicago Entrepreneur

Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data

Annexon shares rose 46% to $6.70 after hours as the company said it will present topline Phase 3 results for one of its flagship programs on Tuesday morning.

Previous post GameStop’s stock could surge again if ‘Roaring Kitty’ returns to YouTube
Next post Marin Software rises 30%, as company expands Amazon integration